Loading...
XNYS
ARMP
Market cap203mUSD
Dec 05, Last price  
5.63USD
1D
-5.22%
1Q
97.54%
Jan 2017
1,179.55%
Name

Armata Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNYS:ARMP chart
P/E
—
P/S
39.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
49.81%
Rev. gr., 5y
-36.56%
Revenues
5m
+14.24%
19,333,00014,073,0009,652,0006,874,0009,864,00010,332,0008,718,000664,000325,000409,000475,000260,000115,00000823,0004,474,0005,508,0004,529,0005,174,000
Net income
-19m
L-72.60%
-23,767,000-14,833,000-14,257,000-19,198,000-33,990,000-16,127,000-20,720,000-1,110,000-58,411,00023,109,000-516,000-18,838,000-12,838,000-12,110,000-19,025,000-22,815,000-23,219,000-36,888,000-69,045,000-18,916,000
CFO
-38m
L-20.82%
-20,096,000-11,230,000-15,523,000-16,391,000-11,636,000-13,882,000-10,305,000-4,281,000-7,448,000-12,572,000-9,781,000-10,589,000-9,192,000-9,382,000-15,582,000-18,270,000-23,575,000-32,481,000-47,423,000-37,551,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
URL
https://www.armatapharma.com/
IPO date
May 20, 1994
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT